U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details


Last Revision: February 15, 2021.

Estimated reading time: 1 minute

CASRN: 76963-41-2

image 135011516 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Because of the low levels of nizatidine in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. No special precautions are required. Histamine H2-antagonists with more extensive use might be preferred in newborns.

Drug Levels

Maternal Levels. Three women who had been breastfeeding for 3 to 8 months were given nizatidine 150 mg orally every 12 hours for 5 doses. Milk nizatidine was measured at several times after the first and fifth doses. Peak milk levels of about 1.2 mg/L occurred about 2 hours after the dose. The mothers excreted a combined average of 96 mcg (range 55 to 137 mcg) of nizatidine into breast milk over the 12 hours after the first and last doses which was less than 0.1% of the mothers' total dose. The half-life in milk averaged less than 2 hours.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Histamine H2-receptor blockade is known to stimulate prolactin secretion.[2] No reports of hyperprolactinemia, galactorrhea or effects on breastfeeding women caused by nizatidine were found as of the revision date. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.


Obermeyer BD, Bergstrom RF, Callaghan JT, et al. Secretion of nizatidine into human breast milk after single and multiple doses. Clin Pharmacol Ther. 1990;47:724–30. [PubMed: 1972674]
Knigge UP. Histaminergic regulation of prolactin secretion. Dan Med Bull. 1990;37:109–24. [PubMed: 2188799]

Substance Identification

Substance Name


CAS Registry Number


Drug Class

Breast Feeding


Anti-Ulcer Agents

Histamine H2 Antagonists

Gastrointestinal Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK501240PMID: 30000299


Related information

Similar articles in PubMed

  • Review Ranitidine.[Drugs and Lactation Database (...]
    Review Ranitidine.
    . Drugs and Lactation Database (LactMed®). 2006
  • General pharmacology of nizatidine in animals.[Arzneimittelforschung. 1989]
    General pharmacology of nizatidine in animals.
    Bemis K, Bendele A, Clemens J, Deldar A, Gidda J, Hamelink J, Holland D, Lamishaw B, McGrath J, Shannon H. Arzneimittelforschung. 1989 Feb; 39(2):240-50.
  • Review Famotidine.[Drugs and Lactation Database (...]
    Review Famotidine.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Misoprostol.[Drugs and Lactation Database (...]
    Review Misoprostol.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Nitazoxanide.[Drugs and Lactation Database (...]
    Review Nitazoxanide.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...